Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. September 2008 02:38 ET | Quelle: PAION AG

PAION Announces Phase I Study With Sedative/Anaesthetic CNS 7056 Progressed to Midazolam Comparison

AACHEN, Germany and CAMBRIDGE, UK, Sept. 22, 2008 (GLOBE NEWSWIRE) -- The biopharmaceutical company PAION AG (ISIN DE000A0B65S3) (Frankfurt:PA8) (London AIM: PAI) today announces that its Phase I...
11. August 2008 02:10 ET | Quelle: PAION AG

Interim Results: PAION AG Reports Half-year Results 2008 and Provides Strategy Update

AACHEN, Germany, Aug. 11, 2008 (PRIME NEWSWIRE) -- The biopharmaceutical company PAION AG (ISIN DE000A0B65S3) (Frankfurt:PA8) (London AIM:PAI) today announced its financial results according to...
28. Februar 2008 03:24 ET | Quelle: PAION AG

PAION's Anticoagulant Solulin Successfully Tested in First-in-man Study

AACHEN, Germany, Feb. 28, 2008 (PRIME NEWSWIRE) -- The biopharmaceutical company PAION AG (Frankfurt:PA8) (Prime Standard) today announced that its drug candidate Solulin has been successfully tested...
27. Juni 2002 02:50 ET | Quelle: PAION AG

PAION GmbH Awarded Euro $4.9 Million Grant for the Development of Protein Production Capabilities

AACHEN, Germany, June 27, 2002 (PRIMEZONE) -- PAION GmbH today announced a Euro 4.9 million grant, awarded over a period of four years, by the State of North Rhine-Westphalia for the development of...